Medically reviewed by Mary Choy, PharmD Farxiga (dapagliflozin) is an orally administered, brand-name medication classified ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

Empaglyde tablets start at Rs 54.90, available in 10 mg to 25 mg including variants - M, L, and S. Empagreat tablets also ...

Dapagliflozin 10 mg: -3.4 mmHg (90% CI -5.8 to -1.0) The secondary endpoint of change in eGFR took a dive within the first week of treatment, ...

New initiators of canagliflozin (n=232,890), dapagliflozin (n=129,881), and empagliflozin (n=295,043) during the study period were included. SGLT2 inhibitor users were only included in the study ...

Dapagliflozin is usually given along with diet and exercise. ... Explore Dapagliflozin brand names commonly used in India and internationally, ... The dose can be increased to 10 mg daily if required.

Despite dapagliflozin not improving diuretic efficiency in the setting of acute HF hospitalization, it was associated with fewer diuretic doses to achieve the same weight change as usual care and ...

Bristol-Myers Squibb Company and AstraZeneca announced results from their Phase 3 trial of dapagliflozin (as monotherapy) for treatment-naïve adults with type 2 diabetes.

ADA 70th Scientific Sessions ORLANDO — Dapagliflozin, an investigational selective sodium-glucose cotransporter-2 inhibitor, improved HbA1c levels and induced further weight loss in combination ...

When dapagliflozin and empagliflozin were compared, the risk of MI/stroke was similar, but dapagliflozin was associated with a higher risk of HF hospitalization (HR 1.19; 95% CI 1.02-1.39).

Farxiga (dapagliflozin) is a prescription, brand-name medication. The Food and Drug Administration (FDA) ... The recommended dosage for this use is 10 mg once per day.

Patients were randomly assigned to receive dapagliflozin 10 mg daily or placebo on top of standard treatment. Roughly two thirds of patients enrolled in DAPA-CKD had type 2 diabetes .